Evidence map›Paper›PMID 41612658›Full record

ArticleJournal of breast cancer2026

Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25).

Sung Gwe Ahn, Sung Hoon Sim, Taewoo Kang, Eun-Kyu Kim, Jeong Eon Lee, Hyeong-Gon Moon, Jee Hyun Ahn, Woosung Lim, Hyun Jo Youn, Hyun-Ah Kim and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05333328 (Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05333328 phase4recruitingnot on this map

Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)

TypeinterventionalSponsorGangnam Severance HospitalRan2023 to 2033Enrolled418ConditionsBreast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer, Premenopausal Breast CancerArmsOvarian function suppression with endocrine treatments
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sung Gwe AhnDepartment of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8778-9686
Sung Hoon SimCenter for Breast Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-1503-1075
Taewoo KangBreast Surgery and Biomedical Research Institute, Pusan National University Hospital, Pusan National University, Busan, Korea.ORCID https://orcid.org/0000-0002-6279-0904
Eun-Kyu KimBreast Care Center, Seoul National University Bundang Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-1318-0939
Jeong Eon LeeDivision of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0037-2456
Hyeong-Gon MoonDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9981-0286
Jee Hyun AhnDivision of Breast Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-4176-3277
Woosung LimDepartment of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2863-9346
Hyun Jo YounDepartment of Surgery, Jeonbuk National University Medical School, Jeonju, Korea.ORCID https://orcid.org/0000-0002-2407-8537
Hyun-Ah KimDepartment of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.ORCID https://orcid.org/0000-0001-9713-2605
Chang Ik YoonDivision of Breast Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-7273-8886
Jisun KimDivision of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4884-6107
Byeongju KangDepartment of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0002-3589-5559
Min Ho ParkDepartment of Surgery, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea.ORCID https://orcid.org/0000-0002-7046-3874
Su Hwan KangDepartment of Surgery, Yeungnam University College of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0002-6508-006X
Lee Su KimDepartment of Surgery, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea.ORCID https://orcid.org/0000-0002-9965-0032
Soong June BaeDepartment of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0012-9694
Yoonwon KookDepartment of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0756-738X
Kwan Ho LeeDepartment of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-6526-3333
Han-Byoel LeeDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0152-575X
Wonshik HanDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7310-0764
Yeon Hee ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. yhparkhmo@skku.edu.ORCID https://orcid.org/0000-0003-4156-9212

Funding

DCGen Co. Ltd.Korean Breast Cancer Study Group
6 · The paper itself

Abstract

purposeWhile postmenopausal women with low recurrence scores in genomic assay may safely forgo adjuvant chemotherapy, the RxPONDER trial demonstrated that premenopausal women with 1-3 positive nodes (pN1) derive significant benefit from adjuvant chemotherapy regardless of low recurrence scores. The INTERSTELLAR trial is evaluating whether ovarian function suppression (OFS) combined with adjuvant endocrine therapy (ET) can offer comparable efficacy to chemotherapy in this specific patient population.

methodsINTERSTELLAR is a prospective, multicenter, single-arm, non-inferiority cohort study enrolling premenopausal women aged ≤ 50 with pT1-2, estrogen receptor +/human epidermal growth factor receptor 2 -, pN1 breast cancer. Genomic risk is assessed using OncoFREE DISCUSSION: Our results may establish evidence supporting the omission of adjuvant chemotherapy in premenopausal women with low genomic risk scores and limited nodal involvement (p-N1), potentially reducing treatment-related morbidity while preserving comparable oncologic outcomes.

trial registrationClinicalTrials.gov Identifier: NCT05333328. Registered on April 18, 2022.

Indexed as

Antineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsPremenopauseReceptors, Estrogen

Identifiers

PMID41612658
PMCPMC12961310

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.